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Chronic beryllium disease (CBD) is a granulomatous lung
disorder that develops in 1e10% of beryllium-exposed
workers.1e4 While the natural history of CBD varies,
increased respiratory symptoms, worsening chest radiog-
raphy and pulmonary physiology are common.5e9 Therapy
for CBD is aimed at suppressing the beryllium-stimulated
immune response, thus improving and/or stabilizing lung
function. First line therapy is usually oral cortico-
steroids,10e13 with other agents, such as methotrexate,
used as steroid sparing therapy.14e16 Despite numerous side
effects, corticosteroids improve symptoms, chest radio-
graphs and lung function in CBD. With treatment, while
some patients may show a response initially, some patients
with CBD worsen clinically.10e13 There are limited alternate
treatment options available.
We report herein, the first randomized, double-blinded
placebo-controlled study undertaken to assess a TNF-
a inhibitor, infliximab in treatment of CBD. Because of TNF-
a’s role in the initiation and perpetuation of granulomatous
inflammation, we hypothesized that infliximab would result
in improvement in Arterial-alveolar (A-aPaO2) gradient
after exercise (primary outcome), pulmonary function,
quality of life and immune markers. The study was con-
ducted at National Jewish Health (NJH) and the Hospital of
University of Pennsylvania (HUP), based on a sarcoidosis
trial.17 We aimed to enroll 20 CBD subjects2,8,18 on stable
doses of corticosteroids and/or methotrexate, with no
evidence of active or chronic infection, malignancy, other
chronic disease, or past treatment with another biologic
with a 3:1 infliximab:placebo ratio administered at 0, 2, 6,
12, 18 and 24weeks. Of the 13 enrolled subjects, 8 in the
infliximab treatment arm and 3 in the placebo arm
completed the study, two withdrew before the first infusion
before the sponsor stopped the study due to slow recruit-
ment. Study endpoints included changes in testing from
baseline to week 28 (four weeks post last infusion) in A-
aPaO2, lung function, SF-36, and blood and bronchoalveolar
lavage (BAL) immune markers.
The demographics of participants were representative
of a CBD population (8 males, 73% and 3 females, 27%) with
a median (range) age of 56.5 (46e74) years. The three in
the placebo arm were all former smokers, while only 3 of0954-6111/$ - see front matter ª 2012 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2012.08.014the 8 in the treatment arm were former smokers (5 were
never). The median  SD duration (years) of prednisone use
was 5.5  7.7 in the placebo group and 2.8  1.6 in the
treatment arm. There were no baseline differences in lung
function (median  SD FEV1 percent predicted: 84  3.92 in
placebo group, 72.5  5.07 in treatment group; FVC
percent predicted: 85  7.79 vs. 69.5  4.8; DLCO/VA:
61  6.17 vs. 71.5  6.27), chest radiography, quality of
life, or immune markers between the placebo and treat-
ment group. The A-a gradient at end of exercise was higher
in the placebo group (75.47  19.78 vs. 31.1  6.16 in the
treatment group, p Z 0.014).
CBD allows the unique opportunity to assess changes in
lung inflammation with treatment. Blood and BAL cells
were obtained from placebo (n Z 2 blood, n Z 2 BAL) and
infliximab treated CBD subjects (n Z 8 blood, n Z 5 BAL).
Infliximab treatment tended to be associated with an
increase in the absolute numbers of lymphocytes/cc in
blood (median  SD, 108  14.6  104/cc vs.
170  18.5  104/cc; pZ 0.078) and the blood lymphocyte
percent (p Z 0.11). The median  SD total BAL WBC count
was reduced, 118.9  106 at baseline to 64.9  106 after
infliximab treatment (p Z 0.06) as was the WBC/cc
(p Z 0.06). In contrast to blood, a decline in the total
number of BAL lymphocytes/cc was noted in the infliximab
treated group (baseline median 9.9  104/cc [range:
2.7e40.2] to 7.3  104/cc [range: 0.8e20.9] after treat-
ment; p Z 0.06), along with a decline in percent lympho-
cytes (31% [range: 20.3e70.8] at baseline to 24% [range:
5.8e48.5]; p Z 0.06). A decline in CD4þ T cells was
observed along with a decline in the CD4þ beryllium-
specific T cells expressing IFN-g and TNF-a (p Z 0.06).
Conversely, an increase in the BAL percent macrophages
was noted with infliximab treatment (58% baseline to 73%;
p Z 0.06). These changes suggest that infliximab therapy
may decrease lung inflammation and the number of path-
ogenic, Be-responsive CD4þ cells recruited to the target
organ. Similar to our findings, in sarcoidosis subjects
treated with infliximab there was a reversal of lymphopenia
and increase in peripheral blood CD4þ T cells.19 The
mechanism by which infliximab affects cell counts in the
blood and BAL is unknown. In rheumatoid arthritis (RA),
infliximab treatment appeared to reverse a dysfunctional
blood Treg cell population, with increase in the number and
ability of the cells to suppress cytokine production.20,21 We.
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population of natural Treg cells are present in the lung of
CBD subjects compared to those with beryllium sensitiza-
tion without disease.22
With regard to clinical parameters explained in this study,
our primary endpoint, the A-aPaO2 proved to be technically
problematic and no difference was found following inflix-
imab treatment. No change was found in symptoms of
dyspnea, FVC or chest radiograph. As the sarcoidosis trial17
noted improvement in a subgroup, we observed that those
with a baseline diffusing capacity for carbon monoxide
(DLCO) <80% predicted (n Z 5, median  SD, 65%  3.24),
improvedwith treatment (72%1.43,pZ0.06). Anumber of
studies have found DLCO to be a good marker of CBD
progression6,7 and response to therapy.10,11 Our power to
detect clinically significant responses was limited because of
small numbers of subjects with a range of disease severity.
We observed improvements in quality of life measures
with treatment. The overall SF-36 mental score for the
infliximab treated group demonstrated a sustained increase
of 4.6 points (p Z 0.08), while the placebo group dropped
7.5 points. Although no change was observed in the overall
physical score, a sub-component, the Bodily Pain Score
improved (54 at baseline to 84, p Z 0.03). In clinical trials
of Crohn’s disease23e26 and RA,26e28 infliximab-treated
groups showed improvement in quality of life scores.
While subjects with RA, psoriasis and ankylosing spondylitis
had lower physical and mental quality of life scores than
our subjects,27 the changes noted after treatment with
infliximab were similar for CBD. In RA, similar to our study,
the greatest change was noted in bodily pain scores, sug-
gesting that infliximab reduces systemic inflammation even
in a lung disease such as CBD. It is possible that CBD activity
measures do not necessarily correlate with patient-
reported health-related quality of life outcomes.29,30
Since compliance is likely closely linked to patient’s
perception of health or improvement, improved SF-36
scores may inform physicianepatient decisions regarding
treatment options.
In summary, we describe the first clinical trial in CBD
with infliximab. The study demonstrated alterations in the
pulmonary immune response as a result of infliximab
treatment. The mechanism by which infliximab affects
this immune response is unknown, but may be more easily
studied in CBD with evaluation of the specific components
of a beryllium-stimulated immune response. Additionally,
while our small numbers limited our ability to detect
significant improvement in lung function, we observed an
improvement in aspects of quality of life with treatment,
and a suggestion that those with more severe gas
exchange as indicated by DLCO may demonstrate clinical
response.
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